ESC Premium Access

Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden

Congress Presentation

About the speaker

Associate Professor Emil Hagstrom

Uppsala University, Uppsala (Sweden)
1 presentation
0 follower

6 more presentations in this session

Intensification of lipid lowering therapy before and after publication of the IMPROVE-IT trial: A temporal analysis from the SPUM-ACS cohort

Speaker: Doctor B. Gencer (Geneva, CH)

Thumbnail

Attributable risk proportion of uncontrolled low-density lipoprotein cholesterol in recurrent acute coronary syndromes

Speaker: Doctor E. Martinez Rey-Ranal (Elche, ES)

Thumbnail

Statin treatment in children with familial hypercholesterolemia in Scandinavia

Speaker: Doctor K. Svendsen (Oslo, NO)

Thumbnail

Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES

Speaker: Professor G. Schwartz (Aurora, US)

Thumbnail

Remnant lipoprotein is a residual risk of future cardiovascular events in patients with stable coronary artery disease and on statin LDL-cholesterol levels less than 70 mg/dl

Speaker: Doctor Y. Fujihara (Kofu, JP)

Thumbnail

Access the full session

How good/bad are we in treating lipids

Speakers: Associate Professor E. Hagstrom, Doctor B. Gencer, Doctor E. Martinez Rey-Ranal, Doctor K. Svendsen, Professor G. Schwartz...
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb